Bibliography
- Widman. Nomenclature of compounds containing nitrogenous nuclei. J Prakt Chem 1888;38:192-3
- Bischler. Orthonitrophenylhydrazine. Ber 1889;22:2801-2
- Bamberger E. Aniline nitration. Chem Ber 1892;25:3201-2
- Arndt F. Ring formation between nitro and amino groups, with production of triazines. Ber 1913;46:3522-3
- Bamberger E. Uber das Phenylhydroxylamin. Chem Ber 1894;27:1548-57
- Wolf FJ, Pfister K, Wislon RM, et al. Benzotriazines. I. A new series of compounds having antimalarial activity. J Am Chem Soc 1954;76:3551-3
- Wolf FJ, Wilson RM, Pfister K, et al. Benzotriazines. II. Synthesis of 3-amino-7-halo-1,2,4-benzotriazine-1-oxides. J Am Chem Soc 1954;76:4611-3
- Rees CW, Adger B, Sale AA, et al. A new synthesis of 1,2,4-benzotriazines. Chem Commun 1971:695-7
- Cerri R, Boido A, Sparatore F. Oxidation and acid-catalyzed cyclization of aldehyde 2-aminophenylhydrazones. Alternative synthesis for 1,2,4-benzotriazines and benzimidazoles. J Heterocyclic Chem 1979;16:1005-8
- Ito S, Tanaka Y, Kakehi A. A novel synthesis of 3-aryl-1,2,4-benzotriazines via N-phenylsulfonyl-N′′-arylbenzamidrazones. Bull Chem Soc Jpn 1982;55:859-64
- Suzuki H, Kawakami T. A convenient synthesis of 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233) and related compounds via nucleophilic aromatic substitution between nitroarenes and guanidine base. Synthesis 1997:855-6
- Katritzky AR, Wang J, Karodia N, et al. Facile synthesis of benzotriazines and indoles by ring-scissions of α-benzotriazol-1-yl hydrazones. Syn commun 1997;27:3963-76
- Hay MP, Gamage SA, Kovacs MS, et al. Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxide as hypoxia-selective analogues of tirapazamine. J Med Chem 2003;46:169-82
- Jiang F, Yang B, Fan L, et al. Synthesis and hypoxic – cytotoxic activity of some 3-amino-1,2,4-benzotriazine-1,4-dioxide derivatives. Bioorg Med Chem Lett 2006;16:4209-13
- Schwesinger H, Sicker D, Wilde H. Synthesis of 4-hydroxycarbonylmethylene-1,2-dihydro-1,2,5-benzotriazepines by diastereoselective cyclization. Pharmazie 1992;47:60-1
- Khodja M, Moulay S, Boutoumi H, Wilde H. Two-step syntheses of 3-methyl and 3-phenyl-1,2,4-benzotriazines. Heteroatom Chem 2006;17:166-72
- Noronha G, Barrett K, Cao J, et al. Discovery and preliminary structure activity relationship studies of novel benzotriazine based compounds as Src inhibitors. Bioorg Med Chem Lett 2006;16:5546-50
- Noronha G, Barrett K, Boccia A, et al. Discovery of [7-(2,6-Dichlorophenyl)-5-methylbenzo[1,2,4]triazin-3-yl]-[4- (2-pyrrolidin-1-ylethoxy)phenyl]amine – a Potent, Orally Active Src Kinase Inhibitor with Anti-tumor Activity in Preclinical Assays. Bioorg Med Chem Lett 2007;17:602-8
- Cao J, Fine R, Gritzen C, et al. The design and preliminary structure-activity relationship studies of benzotriazines as potent inhibitors of Abl and Abl-T315I enzymes. Bioorg Med Chem Lett 2007;17:5812-8
- Regan BA, Hanifin JW, Landes MJ, et al. Anti-inflammatory and analgesic profile of amidines of 3-amino1,2,4-benzotriazine and 3-amino-1,2,4-benzotriazine-1-oxide. J Pharm Sci 1980;69:789-3
- Vaupel P, Schlenger K, Knoop C, et al. Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res 1991;51:3316-22
- Hockel M, Schlenger K, Knoop C, et al. Oxygenation of carcinomas of the uterine cervix: evaluation by computerized O2 tension measurements. Cancer Res 1991;51:6098-02
- Movsas B, Chapman JD, Horwitz EM, et al. Hypoxic regions exist in human prostate carcinoma. Urology 1999;53:11-8
- Kennedy AS, Raleigh JA, Perez GM, et al. Proliferation and hypoxia in human squamous cell carcinoma of the cervix – first report of combined immunohistochemical assays. Int J Radiat Oncol Biol Phys 1997;37:897-905
- Brizel DM, Dodge RK, Clough RW, et al. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol 1999;53:113-7
- Stratford IJ, Workman P. Bioreductive drugs into the next millennium. Anti Cancer Drug Des 1998;13:519-28
- Lin AJ, Cosby LA, Shansky CW. Potential bioreductive alkylating agents. 1. benzoquinone derivatives. J Med Chem 1972;15:1247-52
- Brown JM. SR4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumors. Br J cancer 1993;67:1163-70
- Available from: http://clinicaltrials.gov/ ct/show/NCT00262821?order=1
- Zeman EM, Brown JM, Lemmon MJ. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys 1986;12:1239-42
- Daniels JS, Gates KS. DNA cleavage by the antitumor agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (SR4233): Evidence for involvement of hydroxyl radical. J Am Chem Soc 1996;118:3380-5
- Birincioglu M, Jaruga P, Chowdhury G. DNA base damage by the antitumor agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine). J Am Chem Soc 2003;125:11607-15
- Inbaraj JJ, Motten AG, Chignell CF. Photochemical and photobiological studies of tirapazamine (SR 4233) and related quinoxaline 1,4-di-N -oxide analogues. Chem Res Toxicol 2003;16:164-70
- Nagai K, Carter BJ, Xu J. DNA Cleavage by oxygen radicals produced in the absence of metal ions or light. J Am Chem Soc 1991;113:5099-100
- Anderson RF, Harris TA, Hay MP, et al. Enhanced Conversion of DNA Radical Damage to Double Strand Breaks by 1,2,4-Benzotriazine 1,4-Dioxides Linked to a DNA Binder Compared to Tirapazamine. Chem Res Toxicol 2003;16:1477-1483
- Anderson RF, Shinde SS, Hay MP, et al. Activation of 3-amino-1,2,4-benzotriazine 1,4-dioxide antitumor agents to oxidizing species following their one-electron reduction. J Am Chem Soc 2003;125:748-56
- Hay MP, Hicks KO, Pruijn FB. Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: the role of extravascular transport. J Med Chem 2007; ASAP Article; DOI:10.1021/jm070670g
- Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2006;7:358-64
- Trevino JG, Summy JM, Gallick GE. Src Inhibitors as Potential Therapeutic Agents for Human Cancers. Mini rev Med Chem 2006;6:109-20
- Talamonti MS, Roh MS, Curley SA, et al. Increase in Activity and Level of pp6Oc-erc in Progressive Stages of Human Colorectal Cancer. J Clin Invest 1993;91:53-60
- Wiener JR, Windham TC, Estrella VC, et al. Activated Src protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol Oncol 2003;88:73-9
- Ito H, Gardner-Thorpe J, Zinner MJ, et al. Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness. Surgery 2003;134:221-6
- Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis 2003;22:337-58
- Irby RB, Yeatman TJ. Role of Src expression and activation in human cancer. Oncogene 2000;19:5636-42
- Boschelli DH, Wu B, Sosa ACB, et al. Identification of 7-Phenylaminothieno-[3,2-b]pyridine-6-carbonitriles as a New Class of Src Kinase Inhibitors. J Med Chem 2004;47:6666-8
- Boschelli DH, Wu B, Sosa ACB, et al. Synthesis and Src Kinase Inhibitory Activity of 2-Phenyl- and 2-Thienyl-7-phenylaminothieno[3,2-β ]pyridine-6-carbonitriles. J Med Chem 2005;48:3891-902
- Boschelli DH, Wu B, Sosa ACB, et al. Inhibition of Src kinase activity by 7-[(2,4-dichloro-5-methoxyphenyl)amino]-2-heteroaryl-thieno[3,2-b]pyridine-6-carbonitriles Bioorg Med Chem Lett 2005;15:4681-4
- Manetti F, Locatelli GA, Maga G, et al. A Combination of Docking/Dynamics Simulations and Pharmacophoric Modeling To Discover New Dual c-Src/Abl Kinase Inhibitors. J Med Chem 2006;49:3278-86
- Carraro F, Naldini A, Pucci A, et al. Pyrazolo [3,4-d ]pyrimidines as Potent Antiproliferative and Proapoptotic Agents toward A431 and 8701-BC Cells in Culture via Inhibition of c-Src Phosphorylation. J Med Chem 2006;49:1549-61
- Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999;340:1330-40
- Pendergast AM, Gishizky ML, Havlik MH, et al. SH1 domain autophosphorylation of P210 BCR/ABL is required for transformation but not growth factor independence. Mol Cell Biol 1993;13:1728-36
- Kantarjian H, Cortes J. BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices. J Natl Compr Canc Netw 2008;2:S43-4
- Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2:117-25
- Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354:2531-41
- Tokarski JS, Newitt JA, Chang CY, et al. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 2006;66:5790-7
- Switzerland has granted the first approval for Tasigna® (nilotinib) for Gleevec resistant CML. This was announced on July 25th 2007
- Boschelli DH, Boschelli F. Bosutinib. Dual Src and Abl kinase inhibitor, Treatment of solid tumors, Treatment of CML and Ph+ ALL. Drugs Future 2007;32:481-90
- Willis SG, Lange T, Demehri S, et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005;106:2128-37
- Warmuth M, Simon N, Mitina O, et al. Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases. Blood 2003;101:664-72
- Internal data, unpublished
- Noronha G, Cao J, Chow C, et al. Targeting drug resistant mutations using novel binding interactions - lessons learned from Abl-T315I and their implications in drug design. Front Drug Des Discov 2007;3:121-44
- De Jong PT. Age-related macular degeneration. N Engl J Med 2006;355:1474-85
- Rattner A, Nathans J. Macular degeneration: recent advances and therapeutic opportunities. Nat Rev Neurosci 2006;7:860-72
- Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996;16:4604-13
- Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-7
- Pe'er J, Shweiki D, Itin A, et al. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest 1995;72:638-45
- Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995;92:10457-61
- Eliceiri BP, Paul R, Schwartzberg PL, et al. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell 1999;4:915-24
- Palanki MSS, Akiyama H, Campochiaro P, et al. Development of Prodrug 4-Chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl Benzoate (TG100801): A Topically Administered Therapeutic Candidate in Clinical Trials for the Treatment of Age Related Macular Degeneration. J Med Chem 2008;51:1546-59
- Doukas J, Mahesh S, Umeda N, et al. Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema. Submitted to J Cell Physiol